Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Releases Earnings Results, Misses Expectations By $0.05 EPS
Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) issued its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.39) by $0.05, Briefing.com reports. Foamix Pharmaceuticals had a negative return on equity of 33.20% and a negative net margin of 686.84%. The business had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $1.50 million. During the same quarter in the previous year, the firm posted ($0.27) EPS. Foamix Pharmaceuticals’s revenue was up 6.7% on a year-over-year basis.
Foamix Pharmaceuticals (NASDAQ:FOMX) traded up 4.73% during trading on Wednesday, reaching $4.65. The company had a trading volume of 69,431 shares. Foamix Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $11.27. The company’s market capitalization is $173.09 million. The firm’s 50 day moving average is $5.10 and its 200-day moving average is $6.50.
A number of equities research analysts recently commented on FOMX shares. Zacks Investment Research lowered Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 9th. Credit Suisse Group reissued a “buy” rating and issued a $9.00 price target on shares of Foamix Pharmaceuticals in a report on Wednesday, July 19th.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.
Receive News & Ratings for Foamix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.